Deucravacitinib Improves Patient-Reported Outcomes in Active Psoriatic Arthritis

The selective, allosteric tyrosine kinase 2 inhibitor demonstrated significant and clinically meaningful improvements in PROs versus placebo in a phase 2 trial of patients with PsA.

Related Keywords

,American College Of Rheumatology ,Health Assessment Questionnaire ,Short Form Health ,Stanford University School Of Medicine ,American College ,Health Assessment Questionnaire Disability Index ,Physical Component Summary ,Vibeke Strand ,Stanford University School ,Classification Criteria ,Psoriatic Arthritis ,Psoriatic Impact ,Functional Assessment ,Chronic Illness Therapy Fatigue ,Patient Global Assessment ,Disease Activity ,